Genprex, Inc. announced that the Israel Patent Office granted a patent for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for use in combination with PD-1 antibodies for cancer treatment. This expands Genprex's intellectual property portfolio globally, building on existing patents in major markets. Reqorsa is initially being developed for lung cancer, with preclinical studies showing complementarity with targeted drugs and immunotherapies.

Passage Bio, Inc. announced a workforce restructuring plan on April 28, 2026, as part of its ongoing review of strategic alternatives to maximize shareholder value. The plan involves reducing its workforce by approximately 75% to decrease operating expenses. The company expects to incur approximately $3.3 million in severance and exit costs, primarily in the second quarter of 2026.

Genprex announced positive preclinical data for its diabetes gene therapy candidate, GPX-002 (Pdx1/MafA gene therapy), to be presented at the 2026 ASGCT Annual Meeting. The data demonstrated that GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models by enhancing beta-cell function and maturation. This compelling evidence suggests the technical translatability of the approach for long-term glycemic control in T2D.

Masimo Corporation issued supplemental disclosures to its definitive proxy statement regarding its merger with Danaher Corporation. These disclosures aim to address shareholder litigation and demand letters alleging inadequate information, thereby mitigating risks of delaying the merger. The supplements detail Masimo's prior exploration of strategic alternatives in 2023, where it engaged advisors and contacted potential acquirors, including Danaher, but received no definitive bids, and the subsequent targeted sale process in late 2025 that led to the current merger agreement.

Genprex announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa® Gene Therapy, its lead candidate for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The company also provided updates on its Phase 1/2 Acclaim-1 (NSCLC) and Acclaim-3 (SCLC) clinical trials, reporting positive safety profiles and early signs of efficacy, including prolonged progression-free survival and partial responses in some patients.

Passage Bio, Inc. announced updated interim Phase 1/2 clinical trial data for PBFT02 in frontotemporal dementia caused by progranulin deficiency (FTD-GRN), showing reductions in whole brain and frontotemporal cortex atrophy, stabilization of plasma NfL levels, and robust increases in CSF progranulin. The company has initiated a review of strategic alternatives, including M&A, asset sales, or partnerships, and engaged Wedbush PacGrow as a financial advisor. The FDA indicated a randomized controlled registrational study is required for PBFT02, which the company is evaluating due to ethical, logistical, and financial challenges.

IO Biotech, Inc. ceased operations and filed for Chapter 7 bankruptcy on March 31, 2026, following a review of strategic alternatives. This action will result in the liquidation of the company's assets, the appointment of a Chapter 7 trustee, and the termination of all employees and the board of directors. It is highly unlikely that common stock holders will receive any payment from the bankruptcy proceedings.

Ensysce Biosciences Inc. is exploring strategic alternatives for its business. To maintain enterprise value during this period, the company approved retention packages for three managers and its Chief Financial Officer, totaling approximately $205,475. Board member Lee Rauch resigned, citing disagreement with these compensation packages and prior board actions.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2025. The company is exploring strategic alternatives, including potential partnerships, to enhance stockholder value, manage its cash runway, and define timelines for preclinical and clinical development.

Genprex announced that its collaborators will present positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid) at the 2026 AACR Annual Meeting. The findings advance the understanding of TUSC2's therapeutic mechanisms in lung cancer and identify TROP2 and PTEN as potential biomarkers of resistance to TUSC2 gene therapy in non-small cell lung cancer, which could refine patient selection strategies.

Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the Biologics License Application (BLA) of EBVALLO™. This meeting is a critical step for the company to address the FDA's concerns and determine the next steps for the drug's potential approval.